
US Court Delays FDA Drug Pedigree Requirements
The US Food and Drug Administration has modified its requirements for drug pedigrees accompanying wholesale pharmaceutical transactions, following a US District Court preliminary injunction barring the agency from enforcing certain provisions of the rule that was to have gone into effect on Dec. 1.
Rockville, MD (Dec. 18)
- The US Food and Drug Administration has modified its requirements for drug pedigrees accompanying wholesale pharmaceutical transactions, following a US District Court preliminary injunction barring the agency from enforcing certain provisions of the rule that was to have gone into effect on Dec. 1.
The
Other pedigree requirements remain in effect, FDA says, and wholesalers can comply by providing a pedigree that tracks the drug to initial sale by an authorized distributor. Though the injunction strictly applies only to the Eastern District of New York, to avoid the chaos that would follow a regional patchwork of requirements, FDA indicated that it will apply the Eastern District standard throughout its jurisdiction. (See "
The lawsuit was filed Sept. 20 by online discount outlet RxUSA Wholesale, Inc. (Port Washington, NY,
In issuing the injunction, Judge Seybert confirmed a Magistrate Judge's "
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





